Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
World Health Organization. WHO interim guidelines on clinical management of humans infected by influenza A (H5N1). 20 de febrero de 2004 [citado 17/11/2005]. Disponible en: http://www.who.int/csr/disease/avian_influenza/guidelines/Guidelines_Clinical%20Management_H5N1_rev.pdf
[2.]
K. Ungchusak, P. Auewarakul, S.F. Dowell, R. Kitphati, W. Auwanit, P. Puthavathana, et al.
Probable person-to-person transmission of avian influenza A (H5N1).
N Engl J Med, 352 (2005), pp. 333-340
[3.]
H. Chen, J.D. Smith, S.Y. Zhang, K. Qin, J. Wang, K.S. Li, et al.
Avian flu: H5N1 virus outbreak in migratory waterfowl.
Nature, 436 (2005), pp. 191-192
[4.]
N.T. Liem.
World Health Organization International Avian Influenza Investigation Team, Vietnam, Lim W. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004.
Emerg Infect Dis, 11 (2005), pp. 210-215
[5.]
A.W. Mounts, H. Kwong, H.S. Izurieta.
Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997.
J Infect Dis, 180 (1999), pp. 505-508
[6.]
The writing Comite of the WHO consultation on Human Influenza A/H5.
Avian influenza A (H5N1) infection in humans.
N Engl J Med, 353 (2005), pp. 1374-1385
[7.]
T.T. Hien, N.T. Liem, N.T. Dung, L.T. San, P.P. Mai, N.V. Chau, et al.
Avian influenza A (H5N1) in 10 patients in Vietnam.
N Engl J Med, 350 (2004), pp. 1179-1188
[8.]
C. Schultsz, V.C. Dong, N.VV. Chau, N.T. Le, W. Lim, T.T. Thanh, et al.
Avian influenza H5N1 and healthcare workers.
Emerg Infect Dis, 11 (2005), pp. 1158-1159
[9.]
M.D. De Jong, B.V. Cam, P.T. Qui.
Fatal Avian influenza A (H5N1) in a child presenting with diarrhea followed by coma.
N Engl J Med, 352 (2005), pp. 686-691
[10.]
A. Apisarnthanarak, R. Kitphati, K. Thongphubeth, P. Patoomanunt, P. Anthanont, W. Auwanit, et al.
Atypical avian influenza (H5N1).
Emerg Infect Dis, 10 (2004), pp. 1321-1324
[11.]
T. Chotpitayasunondh, K. Ungchusak, W. Hanshaoworakul, S. Chunsuthiwat, P. Sawanpanyalert, R. Kijphati, et al.
Human disease from influenza A (H5N1), Thailand, 2004.
Emerg Infect Dis, 11 (2005), pp. 201-209
[12.]
A.S. Monto, S. Gravenstein, M. Elliott, M. Colopy, J. Schweinle.
Clinical signs and symptoms predicting influenza infection.
Arch Intern Med, 160 (2000), pp. 3243-3247
[13.]
N.J. Cox, K. Subbarao.
Influenza.
Lancet, 354 (1999), pp. 1277-1282
[14.]
J. McKimm-Breschkin, T. Trivedi, A. Hampson, A. Hay, A. Klimov, M. Tashiro, et al.
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
Antimicrob Agents Chemother, 47 (2003), pp. 2264-2272
[15.]
H.L. Yen, A.S. Monto, R.G. Webster, E.A. Govorkova.
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
J Infect Dis, 192 (2005), pp. 665-672
[16.]
K.G. Nicholson, A.E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, et al.
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.
Lancet, 357 (2001), pp. 1937-1943
[17.]
R.J. Webby, D.R. Pérez, J.S. Coleman, Y. Guan, J.H. Knight, E.A. Govorkova, et al.
Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.
Lancet, 363 (2004), pp. 1099-1103
[18.]
R.B. Belshe, P.M. Mendelman, J. Treanor, J. King, W.C. Gruber, P. Piedra, et al.
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
N Engl J Med, 338 (1998), pp. 1405-1412
[19.]
A. Moscona.
Neuroaminidase inhibitors for influenza.
N Engl J Med, 353 (2005), pp. 1363-1373
[20.]
A.S. Monto, D.P. Robinson, M.L. Herlocher, J.M. Hinson Jr, M.J. Elliott, A. Crisp.
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.
JAMA, 282 (1999), pp. 31-35
[21.]
F.G. Hayden, R.L. Atmar, M. Schilling, C. Johnson, D. Poretz, D.E. Para, et al.
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
N Engl J Med, 341 (1999), pp. 1336-1343
[22.]
A.S. Monto, J. Rotthoff, E. Teich, M.L. Herlocher, R. Truscon, H.L. Yen, et al.
Detection and control of influenza outbreaks in wellvaccinated nursing home populations.
Clin Infect Dis, 39 (2004), pp. 459-464
[23.]
F.G. Hayden, R. Belshe, C. Villanueva, R. Lanno, C. Hughes, I. Small, et al.
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
J Infect Dis, 189 (2004), pp. 440-449
[24.]
K. Stöhr.
Avian influenza and pandemics -research needs and opportunities.
N Engl J Med, 352 (2005), pp. 405-407
[25.]
R.D. Balicer, M. Huerta, I. Grotto.
Tackling the next influenza pandemic.
BMJ, 328 (2004), pp. 1391-1392
Copyright © 2006. Sociedad Española de Salud Pública y Administración Sanitaria
